Hidradenitis Suppurativa Global Market Report 2024 - By Report, Size, Share, Outlook By 2033

The Business Research Company has updated its global market reports, featuring the latest data for 2024 and projections up to 2033

The Business Research Company offers in-depth market insights through Hidradenitis Suppurativa Global Market Report 2024, providing businesses with a competitive advantage by thoroughly analyzing the market structure, including estimates for numerous segments and sub-segments.

Market Size And Growth Forecast:
The hidradenitis suppurativa market size has grown strongly in recent years. It will grow from $1.06 billion in 2023 to $1.15 billion in 2024 at a compound annual growth rate (CAGR) of 8.4%. The growth in the historic period can be attributed to increased diagnosis awareness, limited treatment options, advancements in dermatology, rising disease prevalence, patient advocacy initiatives.

The hidradenitis suppurativa market size is expected to see strong growth in the next few years. It will grow to $1.5 billion in 2028 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to biologic therapies development, precision medicine approaches, clinical trial expansion, global initiatives and funding, healthcare policy support. Major trends in the forecast period include advanced immunomodulatory therapies, telemedicine and remote monitoring, patient-centric care, minimally invasive surgical interventions, personalized lifestyle recommendations.

Get Free Sample Of This Report-
https://www.thebusinessresearchcompany.com/sample.aspx?id=12599&type=smp

Market Segmentation:
The hidradenitis suppurativa market covered in this report is segmented -
1) By Skin Condition: Folliculitis, Pimples, Boils, Deep-Acne
2) By Product: Tablet, Intravenous (IV) Injection
3) By Route Of Administration: Oral, Parenteral
4) By Treatment: Medications, Surgery, Photodynamic Therapy (PDT), Laser Treatment, Other Treatments
5) By End User: Hospital, Specialty Clinic, Homecare, Other End Users

Major Driver - The Rise In The Prevalence Of Skin Diseases
The rise in the prevalence of skin diseases is driving the growth of the hidradenitis suppurativa market going forward. Skin diseases refer to a wide range of skin problems, including those attributed to bacterial infections, viral infections, fungal infections, allergy symptoms, skin malignancies, and parasites. Hidradenitis suppurativa (HS), a chronic and severe skin disorder, is driving the development of new products and services for its management due to increased awareness, accurate diagnosis, a growing patient pool, and research advancements. For instance, in January 2022, according to the report published by the American Cancer Society Inc., a US-based voluntary organization for cancer awareness, the estimated cases of skin cancer increased to 106,110 in 2021, an increase of 5.8% from 100,350 in 2020. Therefore, the rise in the prevalence of skin diseases propels the growth of the hidradenitis suppurativa market.

Competitive Landscape:
Major companies operating in the hidradenitis suppurativa market report are Pfizer Inc., Johnson & Johnson, AbbVie Inc., Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Abbott Laboratories, Eli Lilly and Co Ltd., Amgen Inc., Boehringer Ingelheim International GmbH, UCB S.A., Incyte Corporation, Kyowa Kirin Co. Ltd., Leo Pharma A/S, Almirall S.A., Galapagos NV, Genentech Inc., Tolmar Inc., Alvotech Holdings S.A., Aclaris Therapeutics Inc., Kymera Therapeutics Inc., Acelyrin Inc., AnaptysBio Inc., XBiotech Inc., Arcutis Biotherapeutics Inc., InflaRx N.V., VYNE Therapeutics Inc., Arena Pharmaceuticals Inc., MoonLake Immunotherapeutics AG, Zynerba Pharmaceuticals Inc.

Get Access To The Full Market Report -
https://www.thebusinessresearchcompany.com/report/hidradenitis-suppurativa-global-market-report

Top Trend - Transforming Hidradenitis Suppurativa Treatment Through Innovative Therapies
Utilization of biologics is a key trend gaining popularity in the hidradenitis suppurativa market. Major companies operating in the hidradenitis suppurativa market are investing in research and development, resulting in an approved biologic therapy for hidradenitis suppurativa and sustaining their position in the market. For instance, in June 2023, the European regulatory authority approved Novartis AG, a Switzerland-based pharmaceutical company, for Cosentyx for hidradenitis suppurativa. Cosentyx is the first and only completely human biologic that specifically blocks interleukin-17A, an essential cytokine associated with hidradenitis suppurative disease. Cosentyx is a well-established medication that has been clinically researched for over 14 years.

The Table Of Content For The Market Report Include:
1. Executive Summary
2. Hidradenitis Suppurativa Market Characteristics
3. Hidradenitis Suppurativa Market Trends And Strategies
4. Hidradenitis Suppurativa Market - Macro Economic Scenario
5. Hidradenitis Suppurativa Market Size And Growth
…..
27. Hidradenitis Suppurativa Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model"

About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialize in various industries including manufacturing, healthcare, financial services, chemicals, and technology. The firm has offices located in the UK, the US, and India, along with a network of proficient researchers in 28 countries.

This release was published on openPR.